Evidence map›Paper›PMID 25525413›Full record

ArticleProteome science2014

Effects of mycophenolate mofetil on kidney function and phosphorylation status of renal proteins in Alport COL4A3-deficient mice.

Darinka Todorova Petrova, Frank Christian Schultze, Gunnar Brandhorst, Klaus-Dieter Luchs, Christof Lenz, Henning Urlaub, Diana Rubel, Oliver Gross, Philip D Walson, Michael Oellerich

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proteome science, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 8 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Darinka Todorova PetrovaDepartment of Clinical Pharmacology, Institute of Clinical Chemistry, University Medical Center Goettingen, Robert-Koch-Str. 40, 37099 Goettingen, Germany.
Frank Christian SchultzeClinics of Gastroenterology and Endocrinology, University Medical Center Goettingen, Goettingen, Germany.
Gunnar BrandhorstInstitute of Clinical Chemistry, University Medical Center Goettingen, Goettingen, Germany.
Klaus-Dieter LuchsDepartment of Clinical Pharmacology, University Medical Center Goettingen, Goettingen, Germany.
Christof LenzInstitute of Clinical Chemistry, University Medical Center Goettingen, Goettingen, Germany ; Max Planck Institute for Biophysical Chemistry, Bioanalytical Mass Spectrometry Group, Goettingen, Germany.
Henning UrlaubInstitute of Clinical Chemistry, University Medical Center Goettingen, Goettingen, Germany ; Max Planck Institute for Biophysical Chemistry, Bioanalytical Mass Spectrometry Group, Goettingen, Germany.
Diana RubelClinics of Nephrology and Rheumatology, University Medical Center Goettingen, Goettingen, Germany.
Oliver GrossClinics of Nephrology and Rheumatology, University Medical Center Goettingen, Goettingen, Germany.
Philip D WalsonDepartment of Clinical Pharmacology, University Medical Center Goettingen, Goettingen, Germany.
Michael OellerichDepartment of Clinical Pharmacology, University Medical Center Goettingen, Goettingen, Germany.
University of Göttingen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe investigated the effects of mycophenolate mofetil (MMF) on kidney function and on protein phosphorylation in a mouse model for the human Alport syndrome.

methodsCOL4A3-deficient (COL4A3-/-) mice were randomly allocated to receive a placebo (PLC COL4A3-/-) or MMF treatment (MMF COL4A3-/-). Wild type mice (WT) were used as controls. Changes in serum creatinine, total protein and blood urea nitrogen (BUN), concentrations of mycophenolic acid (MPA) and its glucuronide metabolite (MPAG), serum protein electrophoresis, urine dipstick chemistry and sediment were measured. Changes in the phosphorylation status of renal proteins and histology were analyzed.

resultsMMF influenced kidney function and protein phosphorylation. Serum creatinine and BUN were lower in MMF treated compared to PLC treated COL4A3-/- mice. Serum albumin and alpha-1 globulins were significantly decreased while serum creatinine, alpha-2 globulins, urine dipstick protein, leukocyte esterase, hemoglobin and red blood cells were all increased in both COL4A3-/- groups compared to WT. Differential 2DE-gel analysis identified six phosphorylated kidney protein spots that were significantly altered by MMF.

conclusionsThese data suggest that the MMF treatment in this murine model moderately improved kidney function and reversed the phosphorylation status of six renal phosphoprotein spots to that seen in WT mice.

Indexed as

Alport syndromeKidney fibrosisMycophenolic acidProtein phosphorylation

Identifiers

PMID25525413
PMCPMC4269973
OpenAlexW2100062354

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.